ClinicalTrials.gg

Myocardial Infarction clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,273 studies for Myocardial Infarction across more than 10 countries. 374 are recruiting or about to start. 1,217 of them are mainly about Myocardial Infarction (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 5 narrower conditions too, such as ST Elevation Myocardial Infarction: 3,336 studies, 675 open.

ClinicalTrials.gov finds 3,922 studies for Myocardial Infarction. How that becomes 2,274 here

This page counts the studies the registry files under Myocardial Infarction, and those it files under no condition that list Myocardial Infarctionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 3,922Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,058Filed under a narrower condition, counted on its own pageST Elevation Myocardial Infarction 650 · Shock, Cardiogenic 250 · Non-ST Elevated Myocardial Infarction 108 · Anterior Wall Myocardial Infarction 16 · MINOCA 16
  3. −275List Myocardial Infarction as a condition, but the registry did not file them under itMost often written as “Acute Myocardial Infarction” (184), “Acute Myocardial Infarction (AMI)” (23), and “Coronary Artery Disease With Myocardial Infarction” (8). The registry filed them under other conditions only, most often Acute Coronary Syndrome (47) and Coronary Artery Disease (38).
  4. −315Match it another way245 name it in the title, 46 in a keyword, and 24 by a synonym or other text the search reads.
  5. 2,274The count on this page305 of them list Myocardial Infarction in their own words; the registry filed them under no condition.

Status

Completed
1,270
Status unknown
362
Recruiting
256
Terminated
117
Not yet recruiting
97
Active, not recruiting
90

Phase

Phase 4
261
Phase 3
246
Phase 2
221
Phase 1
84
Early Phase 1
6

Where

United States
440
China
196
United Kingdom
175
Canada
171
France
168
Germany
159

Who develops what

Add Myocardial Infarction to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 12 companies, 5 with this as their studies’ main aim; 4 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Novartis, Amgen and AO GENERIUM here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AspirinRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07153744 · Shanghai Hutchison Pharmaceuticals Limited · Phase 4 · live · comparator · “Aspirin” · registered Aug 2025
  • NCT02227368 · AstraZeneca · Phase 2 · comparator · “Comparator” · registered Aug 2014
  • NCT00684203 · Merck & Co., Inc · Phase 2 · background · “Aspirin” · registered May 2008
  • NCT00642811 · AstraZeneca · Phase 2 · background · “Aspirin” · registered Mar 2008
  • NCT00557921 · Cogentus Pharmaceuticals · Phase 3 · comparator · “Plavix (clopidogrel 75 mg) and aspirin” · registered Nov 2007
Bayer25% of its industry studies11 study
TenecteplaseRecent, limited
Evidence
  • NCT05601999 · AO GENERIUM · Phase 3 · comparator · “Metalyse” · registered Oct 2022
  • NCT02301910 · Supergene, LLC · Phase 3 · comparator · “Tenecteplase” · registered Nov 2014
Boehringer Ingelheim50% of its industry studiesEU: Boehringer Ingelheim (EMA 2001)11 study
Tissue Plasminogen ActivatorRecent, limited
Evidence
  • NCT07146360 · AO GENERIUM · Phase 3 · comparator · “Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)” · registered Aug 2025
Boehringer Ingelheim28% of its industry studiesUS: Hoffmann-La Roche (FDA 1987)11 study

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ziltivekimab☆ Track2 live phase-3 studies: NCT06118281, NCT07301034Novo Nordisk A/S
pacibekitug☆ Track1 live phase-3 study: NCT07938411Novartis

The 2 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 29 Jan 2027 est.ziltivekimab · Novo Nordisk A/S · Phase 3 main aimNCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — primary endpoint: Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal stroke · 10,000 enrolled
  • 8 Feb 2027 est.orticumab · Abcentra · Phase 2 named, not the main aimNCT06927739 Focused Orticumab Research for Treating Inflammation in Coronary Arteries — primary endpoint: Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD and LCX) for orticumab compared to placebo at 24 weeks · 240 enrolled
  • 30 Jun 2027 est.Xolatryp · Nyrada Pty Ltd · Phase 2 named, not the main aimNCT07362446 Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction — primary endpoint: Incidence of Adverse Events · 300 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myocardial Infarction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here NSAIDs 7 open · SGLT2 inhibitors 7 open · P2Y12 inhibitors 4 open · Factor Xa inhibitors 4 open · Beta blockers 3 open

Coming up

117studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger. 17 (7%) take children under 18. 2 (1%) are for women only and 0 (0%) for men only; 27 (11%) take healthy volunteers.

Recruiting studies that take each age, of 256
AgeWomenMen
1011 (4%)11 (4%)
18201 (79%)200 (78%)
30232 (91%)230 (90%)
40237 (93%)235 (92%)
50244 (95%)242 (95%)
65247 (96%)246 (96%)
75240 (94%)239 (93%)
85199 (78%)198 (77%)

Across all 2,273 studies, recruiting or not: 14% stop at 75 or younger and 4% at 65; 10% take children; 1% are for women only and 3% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myocardial Infarction studies take

Of 87 phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 126 mo8–40 · 13 studies——
Phase 227 mo19–42 · 45 studies——
Phase 344 mo30–77 · 57 studies—41 mo24–73 · 33 studies
Phase 442 mo22–78 · 87 studies—42 mo22–78 · 83 studies
Interventional, no phase34 mo15–57 · 355 studies31 mo15–49 · 33 studies35 mo14–58 · 322 studies
Observational48 mo17–114 · 334 studies17 mo7–32 · 37 studies55 mo20–140 · 297 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 2,273. Browse all 2,273 → or search them.